Literature DB >> 12133935

Generation of CD4(+)CD45RA(+) effector T cells by stimulation in the presence of cyclic adenosine 5'-monophosphate-elevating agents.

Ana Suárez1, Lourdes Mozo, Carmen Gutiérrez.   

Abstract

After TCR cross-linking, naive CD4(+)CD45RA(+) T cells switch to the expression of the CD45RO isoform and acquire effector functions. In this study we have shown that cAMP-elevating agents added to anti-CD3- and anti-CD28-stimulated cultures of T lymphocytes prevent acquisition of the CD45RO(+) phenotype and lead to the generation of a new subpopulation of primed CD4(+)CD45RA(+) effector cells (cAMP-primed CD45RA). These cells displayed a low apoptotic index, as the presence of dibutyryl cAMP (dbcAMP)-rescued cells from CD3/CD28 induced apoptosis. Inhibition of CD45 splicing by dbcAMP was not reverted by addition of exogenous IL-2. cAMP-primed CD45RA cells had a phenotype characteristic of memory/effector T lymphocytes, as they showed an up-regulated expression of CD2, CD44, and CD11a molecules, while the levels of CD62L Ag were down-regulated. These cells also expressed the activation markers CD30, CD71, and HLA class II Ags at an even higher level than CD3/CD28-stimulated cells in the absence of dbcAMP. In agreement with this finding, cAMP-primed CD45RA cells were very efficient in triggering allogenic responses in a MLR. In addition, cAMP-primed CD45RA cells produce considerable amounts of the Th2 cytokines, IL-4, IL-10, and IL-13, whereas the production of IFN-gamma and TNF-alpha was nearly undetectable. The elevated production of IL-13 by neonatal and adult cAMP-primed CD45RA cells was specially noticeable. The cAMP-dependent inhibition of CD45 splicing was not caused by the production of immunosuppressor cytokines. These results suggest that within the pool of CD4(+)CD45RA(+) cells there is a subpopulation of effector lymphocytes generated by activation in the presence of cAMP-elevating agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133935     DOI: 10.4049/jimmunol.169.3.1159

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Persistence and emergence of X4 virus in HIV infection.

Authors:  Ariel D Weinberger; Alan S Perelson
Journal:  Math Biosci Eng       Date:  2011-04       Impact factor: 2.080

2.  Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death.

Authors:  Leonóra Himer; Balázs Csóka; Zsolt Selmeczy; Balázs Koscsó; Tímea Pócza; Pál Pacher; Zoltán H Németh; Edwin A Deitch; E Sylvester Vizi; Bruce N Cronstein; György Haskó
Journal:  FASEB J       Date:  2010-04-06       Impact factor: 5.191

Review 3.  HLA-G in organ transplantation: towards clinical applications.

Authors:  Frederic Deschaseaux; Diego Delgado; Vito Pistoia; Massimo Giuliani; Fabio Morandi; Antoine Durrbach
Journal:  Cell Mol Life Sci       Date:  2010-11-20       Impact factor: 9.261

4.  Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls.

Authors:  Sheida Yahyazadeh; Nafiseh Esmaeil; Vahid Shaygannejad; Omid Mirmosayyeb
Journal:  Res Pharm Sci       Date:  2022-04-18

5.  Impact of cAMP on the T-cell response to type II collagen.

Authors:  Patricia Ozegbe; Andrew D Foey; Salman Ahmed; Richard O Williams
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

Review 6.  Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Authors:  Selena Vigano; Dimitrios Alatzoglou; Melita Irving; Christine Ménétrier-Caux; Christophe Caux; Pedro Romero; George Coukos
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

7.  Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection.

Authors:  Ariel D Weinberger; Alan S Perelson; Ruy M Ribeiro; Leor S Weinberger
Journal:  PLoS Comput Biol       Date:  2009-08-14       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.